BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report released on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of BioLineRx in a research note on Wednesday, November 6th.

BioLineRx Stock Down 14.0 %

Shares of BLRX opened at $0.28 on Friday. BioLineRx has a 52 week low of $0.26 and a 52 week high of $1.89. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34. The company has a market capitalization of $22.23 million, a price-to-earnings ratio of -0.62 and a beta of 1.48. The stock’s 50-day moving average price is $0.49 and its 200-day moving average price is $0.61.

Hedge Funds Weigh In On BioLineRx

Hedge funds have recently bought and sold shares of the business. PVG Asset Management Corp acquired a new stake in shares of BioLineRx in the second quarter valued at approximately $70,000. Atria Investments Inc lifted its holdings in BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC purchased a new stake in BioLineRx during the 2nd quarter worth about $462,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.